Breo Ellipta 200/25 mcg

Description

Breo Ellipta 200/25 mcg
(Fluticasone Furoate 200 mcg / Vilanterol 25 mcg)

Description:
Breo Ellipta 200/25 mcg is a once-daily, fixed-dose combination inhalation medication used to treat chronic obstructive pulmonary disease (COPD) and asthma in adults. It contains fluticasone furoate, a corticosteroid that reduces inflammation in the airways, and vilanterol, a long-acting beta-agonist (LABA) that helps to relax the smooth muscles around the airways, improving airflow. This combination of anti-inflammatory and bronchodilator action helps control symptoms, prevent exacerbations, and improve lung function.

Breo Ellipta 200/25 mcg is used as a maintenance treatment for individuals with COPD or asthma and is not intended for the immediate relief of acute breathing problems. By reducing inflammation and helping to keep the airways open, it offers 24-hour relief from wheezing, shortness of breath, coughing, and chest tightness.

Key Features:

• Dual-Action Therapy: Combines fluticasone furoate (200 mcg), a long-acting corticosteroid that reduces airway inflammation, with vilanterol (25 mcg), a long-acting beta-agonist (LABA) that helps keep airways open by relaxing the muscles around them.
• Once-Daily Dosing: Provides 24-hour relief with a single dose, simplifying the treatment regimen by requiring only one inhalation per day.
• Effective for COPD & Asthma: Approved for the long-term maintenance treatment of COPD (including chronic bronchitis and emphysema) and asthma in adults, helping to prevent flare-ups and manage chronic symptoms.
• Ellipta Inhaler Technology: The Ellipta inhaler is designed for ease of use, providing a pre-loaded, accurate dose of medication with each inhalation. It’s designed to be simple to operate with minimal steps, ensuring correct and reliable dosing.
• Improved Lung Function: Helps reduce symptoms such as coughing, wheezing, and shortness of breath, and can improve lung function over time for individuals with chronic respiratory conditions.